The Week in Review: Oct 5 – Oct 19, 2018

Friday, Oct 19, 2018 News Recap: Want a Say in the Direction of HepCBC? Online or in person, attend HepCBC's Annual General Meeting. Actual event is Saturday, November 3rd from 2 to 3 pm. 1947 Cook Street. UC researchers recommend universal screening to tackle rise in Hepatitis C. Physicians are encountering a growing number of younger patients who are testing positive for hepatitis C virus (HCV) fueled largely by the opioid crisis impacting com...

HepCBC at the Coast Mental Health Clubhouse

On October 12, 2018, HepCBC sent two volunteers to man a hepatitis B and hepatitis C info booth at the Coast Mental Health Clubhouse (11th Avenue and Sophia Street in Vancouver). Leon Anderson and Cheryl Reitz met with many friendly clients and staff members at the Clubhouse for about 90 minutes. Our table, next to the entrance to the lunchroom, allowed us to have great conversations with people (lining up there for the mid-day meal) about the latest deve

HepCBC Info Tables Pop Up in Variety of September Venues

This September saw HepCBC cooperating with many different groups in Victoria and Vancouver to inform people from diverse communities about hepatitis B and C. These included members of First Nations, Chinese, IVDU (both active and in recovery), and homeless (or housing-challenged) communities. Three of the events included partnership with Vancouver Infectious Diseases Centre (VIDC) who held popular HCV screening clinics on site. Two MLA’s visited us! (PS:

The Week in Review: October 27 – November 4, 2017

Friday, November 4, 2017 News Recap: Access to Treatment Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...